BioStock

Prenumeration

BioInvent International AB: BioStock: BioInvent and MSD to evaluate new metastatic melanoma treatment

2024-07-19 11:00:37

BioInvent, known for its innovative cancer immunotherapies, is expanding its partnership with MSD to test BI-1607 in combination with ipilimumab and KEYTRUDA in a phase II trial for metastatic melanoma. The phase II study aims to enhance the efficacy of these existing treatments while reducing toxicity, potentially offering a more tolerable and effective treatment regimen.

Read the article at biostock.se:

BioInvent and MSD to evaluate new metastatic melanoma treatment (https://www.biostock.se/en/2024/07/bioinvent-and-msd-expand-partnership-to-evaluate-new-metastatic-melanoma-treatment/)
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

BioStock

Prenumeration

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden